Transforming the work of early-stage drug discovery through bioprocess informatics.
Drug discovery has historically advanced by synergy and chance. These are proving insufficient to meet the needs of the marketplace and the demands of modern medicine. We describe our strategic approaches to building and employing flexible informatics tools to transform and improve the workflows and efficiencies of the early-stages of target development in drug discovery. We contrast our approach to strategies that have recently evolved at startup biotechnology companies who use similar technological approaches to drug development but who are less encumbered by precedent and history.
Holzman
Thomas F
TF
Protein Biochemistry, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. thomas.holzman@abbott.com
Hebert
Eric J
EJ
D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration* / Q000639:trends; D005285:Fermentation; D006801:Humans; D048088:Informatics / Q000379:methods*; D013678:Technology, Pharmaceutical / Q000639:trends*